Victory Capital Management
HTGM

Victory Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Victory Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-92
Closed -$6K – 3531
2020
Q1 		$6K Buy
+92
New +$9.01K ﹤0.01% 3482
2019
Q4 		– Sell
-23
Closed -$3K – 3515
2019
Q3 		$3K Buy
+23
New +$4.63K ﹤0.01% 3597

Other funds holding HTGM

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KM
Kalos Management Alpharetta, Georgia $46.6M AUM 11.52% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Victory Capital Management's HTGM Position: Q2 2020 in Review

Victory Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2020, closing a stake of 92 shares — an estimated $6K sold.

Victory Capital Management first reported a position in HTGM in Q3 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2020. 28 funds tracked by Wall St. Rank hold HTGM as of Q2 2020.

  • Victory Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 92 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $6K in Q1 2020.
  • 28 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.